Importantly, the SI of ZMN against IAV evaluated in this study are in the same range as those for other HTAs, like the DHODH inhibitors Brequinar, Teriflunomide, S312 or S416 [27,28], the receptor tyrosine kinase inhibitors Tyrphostin A9 or AG879 [29], the IMPDH inhibitor N30 [30], the Akt inhibitor MK2206 [31] or the XPO1 antagonist Verdinexor [32], showing that ZMN achieves an effective anti-influenza activity without disproportionately harming host cells, making it competitive with other HTAs. The gene discussed is XPO1; the disease is influenza.